24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Virtual Doc Visits Suffice for Many With Neurological DisordersBPA Levels in Humans Are Underestimated: StudyCleaner Air Quickly Brings Big Health Benefits, Study FindsAll 50 States Now Reporting Cases of Severe Vaping-Linked Lung Injury3 Drugs for Severe Epileptic Seizures Are Equally Effective: StudyStudy Casts Doubt on Use of Common Heart Failure Drugs'Mobile Stroke Units' Help Rush Treatment to PatientsDistracted by Their Smartphones, Pedestrians Are Landing in the ERVaping May Have Triggered Lung Illness Typically Only Seen in MetalworkersMore Than 100 E. Coli Illnesses Now Linked to Romaine LettuceLow-Dose Aspirin Might Cut Cancer Risk, Especially for Overweight PeopleEspecially in the Young, Cholesterol Is No Friend to the HeartAre E-Scooters a Quick Ticket to the ER?Uncontrolled Asthma a Danger to Pregnant Women, BabiesHealth Tip: Common Causes of Knee PainSome Cities' Smog Can Ruin Your VacationParkinson's Treatment Has Unexpected Side EffectHeart Attack at 44 Helped Her Realize Diabetes' DangersCleaner Teeth, Healthier Heart?Obesity Might Weaken Some Drugs' Effectiveness Against AFibHow to Prevent Holiday HeadachesAir Pollution May Up Glaucoma RiskHealth Tip: Causes of Stomach UlcersHealth Tip: Treating ShinglesLeg Pain Could Spell Peripheral Artery Disease for SomeEven in Small Doses, Air Pollution Harms Older AmericansDon't Let Allergies Spoil Your HolidaysGot Chronic Heartburn? Easy Does It During the Thanksgiving FeastAHA News: Flu Prevention Strategies Beyond Getting a Shot and Washing Your HandsUltrasound Treatment Might Ease Parkinson's TremorsPopular Heartburn Drugs May Up Odds of Stomach BugGunshot Wounds Have Long-Term Health Consequences: StudyU.S. Poison Centers Field More Calls About Psychoactive Substances: StudyMore E. coli Illnesses Linked to Tainted Romaine LettuceFDA Approves First System to Insert Ear Tubes Under Local AnesthesiaFDA Approves Oxbryta for Treatment of Sickle Cell DiseaseWhere 'Superbugs' Lurk in Your Home - and How to Stop ThemPlay It Safe With Holiday FoodsCaffeine, Cough Medicines: What's in the Average Blood TransfusionVitamin E Compound Likely Culprit Behind Vaping Lung Illnesses, Study FindsDramatic Rise in Eye Injuries From BB and Paintball GunsObesity May Change the Teen Brain, MRI Study ShowsDon't Eat Romaine Lettuce Grown in Salinas, Calif., Due to E. Coli: FDAMusic Career Might Bring Ringing in the EarsBacteria Could Be Weapon Against Mosquito-Borne DengueHealth Tip: Five Common First-Aid MythsInfants May Not Be as Immune to Measles as ThoughtDoctors Spot a New, Severe Lung Illness Tied to VapingAHA News: Obesity, Other Factors May Speed Up Brain AgingPackaged Caesar Salad Suspected as Possible Source in E. coli Outbreak
Questions and AnswersLinks
Related Topics

Diabetes

Fetroja Approved to Treat Complicated Urinary Tract Infections


HealthDay News
Updated: Nov 15th 2019

new article illustration

FRIDAY, Nov. 15, 2019 (HealthDay News) -- Antibacterial drug Fetroja (cefiderocol) has been approved to treat patients aged 18 years and older with complicated urinary tract infections (cUTIs), the U.S. Food and Drug Administration announced yesterday.

The drug is indicated for patients with limited or no alternative treatment options for cUTI, including kidney infections caused by susceptible Gram-negative microorganisms. Dosage is 2 g of Fetroja every eight hours administered by intravenous infusion over three hours. Dose adjustments are required based on creatinine clearance. Prescription labeling on Fetroja includes a warning for a higher all-cause mortality rate in Fetroja-treated critically ill patients with multidrug-resistant Gram-negative bacterial infections.

Approval of Fetroja was based on safety and efficacy data from 448 patients with cUTI in the APEKS-cUTI study. Symptoms resolved and bacteria were eradicated in 72.6 percent of patients who received Fetroja seven days after treatment completion versus 54.6 percent of patients who received imipenem/cilastatin. Clinical response rates were similar between the two groups of patients.

The cause of the higher mortality rate with Fetroja in critically ill patients with multidrug-resistant Gram-negative bacterial infections is unknown. According to the FDA, some of the deaths were due to worsening or complications of infection or underlying comorbidities. This higher mortality rate was also seen among patients treated for hospital-acquired/ventilator-associated pneumonia, bloodstream infections, or sepsis. The agency noted that the safety and efficacy of Fetroja for treating these types of infections has not been determined.

The most commonly reported adverse reactions with Fetroja included diarrhea, constipation, nausea, vomiting, elevations in liver tests, rash, infusion site reactions, candidiasis, cough, headache, and hypokalemia. Patients who have had severe hypersensitivity to beta-lactam antibacterial drugs should not take Fetroja.

Approval was granted to Shionogi & Co.

More Information